Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11462MR)

This product GTTS-WQ11462MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11462MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9117MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMGN242
GTTS-WQ4562MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-936564
GTTS-WQ5606MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP791
GTTS-WQ5656MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDX-011
GTTS-WQ5087MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CAM-3001
GTTS-WQ2167MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALD-518
GTTS-WQ9206MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-106
GTTS-WQ6693MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA DNIB0600A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW